The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Market Value Expansion Is Expected For The Choroidal Neovascularization Market Over The Forecast Period?
The choroidal neovascularization market has experienced robust growth recently. It is projected to increase from $4.18 billion in 2025 to $4.5 billion in 2026, representing a compound annual growth rate (CAGR) of 7.7%. This historic expansion has been driven by factors such as the increasing prevalence of age-related macular degeneration, a rise in diabetic eye disease cases, the expansion of ophthalmology clinics, the availability of anti-angiogenic drugs, and improvements in retinal diagnostic capabilities.
The choroidal neovascularization market is projected to demonstrate significant growth over the next few years. It is expected to expand to $5.99 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.4%. This expansion during the forecast period can be attributed to an aging global population, a heightened emphasis on timely ophthalmic intervention, the wider adoption of combination therapy approaches, increasing financial commitments to retinal disease research, and the rising implementation of personalized treatment protocols. Prominent trends within this period include the increased uptake of anti-VEGF therapies, a growing reliance on treat-and-extend regimens, a surging requirement for early CNV diagnosis, the broader application of advanced retinal imaging techniques, and an intensified focus on therapies aimed at preserving vision.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp
Which Growth Drivers Are Expected To Support The Choroidal Neovascularization Market Forward?
The increasing incidence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market in the future. Age-related macular degeneration (AMD) is an ocular condition characterized by progressive harm to the macula, resulting in the impairment of central vision, predominantly among the elderly. The growing occurrence of age-related macular degeneration (AMD) stems from an aging demographic, extended longevity, evolving lifestyle habits, hereditary predispositions, and heightened vulnerability to environmental hazards. Choroidal neovascularization (CNV) plays a role in aiding age-related macular degeneration (AMD) sufferers through its involvement in the emergence of wet AMD, a condition where the proliferation of atypical blood vessels under the retina causes a decline in vision, necessitating sophisticated interventions like anti-VEGF therapy to control choroidal neovascularization (CNV) and decelerate the advancement of age-related macular degeneration (AMD), thereby helping to maintain central vision for those impacted. For example, by 2025, the UHN Foundation, Canada-Based official fundraising arm, reports that age-related macular degeneration (AMD) will be the leading reason for substantial, permanent vision impairment in people aged over 50. While it currently impacts more than 200 million individuals globally, this figure is predicted to reach 288 million by 2040. Consequently, the growing incidence of age-related macular degeneration is fueling the expansion of the choroidal neovascularization market.
Which Segment-Based Categories Are Covered In The Choroidal Neovascularization Market?
The choroidal neovascularization market covered in this report is segmented –
1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy
What Trends Are Influencing The Choroidal Neovascularization Market?
Major entities operating in the choroidal neovascularization market are concentrating on creating innovative treatments, such as photodynamic therapy, to provide eye care professionals with precise, efficient treatment alternatives that improve patient outcomes and the delivery of care. Photodynamic therapy (PDT) is a medical process that utilizes a photosensitizing agent activated by light to specifically target and destroy abnormal or cancerous cells. For example, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, disclosed the ML6710i photodynamic laser, which was approved by the Food and Drug Administration, a US-based federal agency. This therapy is authorized for use with Bausch + Lomb’s VISUDYNE therapy, which is specifically designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This modern, mobile ophthalmic laser provides a targeted approach for treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.
Which Organizations Are Involved In The Choroidal Neovascularization Market?
Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated
Access The Complete Choroidal Neovascularization Market Report:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report
Which Area Represents The Largest Portion Of The Choroidal Neovascularization Market?
North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Choroidal Neovascularization Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp
Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company
Cartilage Repair Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cartilage-repair-global-market-report
Knee Cartilage Repair Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/knee-cartilage-repair-global-market-report
Regenerative Medicine For Cartilage Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model